Search Medical Condition
Please enter condition
Please choose location from dropdown

DeBary, Florida Clinical Trials

A listing of DeBary, Florida clinical trials actively recruiting patient volunteers.

RESULTS

Found (110) clinical trials

Saroglitazar Magnesium in Patients With Nonalcoholic Fatty Liver Disease and/or Nonalcoholic Steatohepatitis

This is a randomized, double-blind, placebo-controlled study in up to 104 patients with a diagnosis of NAFLD and/or NASH. The study will be conducted over a period of up to 22 weeks and will include an optional Prescreening, Screening (Days -35 to -7) Phase, a 16-week Treatment Phase following randomization ...

Phase

4.22 miles

Learn More »

Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)

The purpose of this study is to evaluate the efficacy and safety of ruxolitinib versus anagrelide in subjects with essential thrombocythemia who are resistant to or intolerant of hydroxyurea.

Phase

4.22 miles

Learn More »

A phase III Efficacy and Safety of 3 week fixed dose asenapin treatment in pediatric acute manic or mixed episodes associated with Bipolar 1 Disorder in adolescents. Patient Inclustion Criteria: The subject is aged between 10 and 17 years, inclusive. The subject suffers from bipolar 1 disorder.

Phase

4.22 miles

Learn More »

An 8 week, placebo-controlled, double-blind, randomized, fixed-dose efficacy and safety study of asenapine in adolescent subjects with schizophrenia. Patient Inclustion Criteria: The subject is aged between 10 and 17 years, inclusive. The subject suffers from schizophrenia.

Phase

4.22 miles

Learn More »

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Once a Day, TAK-375SL 0.1, 0.4, and 0.8 mg as an Adjunctive Therapy to Treatment-as-Usual in the Maintenance Treatment of Bipolar 1 Disorder in Adult Subjects Patient Inclustion Criteria: The subject is a man or woman ...

Phase

4.22 miles

Learn More »

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Once a Day, TAK-375 (Ramelteon) Tablet for Sublingual Administration (TAK-375SL Tablet) 0.1, 0.4, and 0.8 mg as an Adjunctive Therapy in the Treatment of Acute Depressive Episodes Associated with Bipolar 1 Disorder in Adult Subjects. Patient ...

Phase

4.22 miles

Learn More »

A Safety and Efficacy Study to Evaluate Luspatercept in Subjects With Myeloproliferative Neoplasm-associated Myelofibrosis Who Have Anemia With and Without Red Blood Cell-transfusion Dependence

Subjects satisfying the eligibility criteria will be assigned to 1 of the following cohorts (which are enrolling in parallel) based on their eligibility: Cohort 1: will contain up to 20 subjects with anemia only that are not currently receiving RBC transfusions (these subjects will be referred to as "anemia only" ...

Phase

4.22 miles

Learn More »

Study to Evaluate the Efficacy and Safety of APL-2 in Patients With PNH

Evaluation of the Efficacy and Safety of APL-2 in Patients with Paroxysmal Nocturnal Hemoglobinuria

Phase

4.22 miles

Learn More »

Integrated Cancer Repository for Cancer Research

The integrated Cancer Repository for Cancer Research (iCaRe2 http://icare2project.org) is a unique sociotechnical resource for the collection and management of cancer and health-related data at the Fred & Pamela Buffett Cancer Center at University of Nebraska Medical Center (UNMC). The iCaRe2 is a multi-center, semantically-interoperable and easily-customizable cancer data resource ...

Phase N/A

4.22 miles

Learn More »

Pharmacokinetics and Pharmacodynamics Study of SEG101 (Crizanlizumab) in Sickle Cell Disease (SCD) Patients With Vaso- Occlusive Crisis (VOC)

The purpose of the CSEG101A2202 study is to characterize the PK and PD of SEG101/crizanlizumab at 5 mg/kg and to evaluate the safety and efficacy of SEG101/crizanlizumab in SCD patients. Study CSEG101A2202 is designed as a Phase II, multicenter, open-label study. The first 45 patients (to identify 27 evaluable patients) ...

Phase

4.22 miles

Learn More »